RIGEL PHARMACEUTICALS INC — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Rigel filed three equity incentive plans (2018 Plan, Inducement Plan, 2000 ESPP) with standard vesting, exercise, and forfeiture terms, and an amended revolving credit facility with MidCap Funding IV Trust dated May 5, 2026. The credit agreement provides a revolving commitment (amount redacted), minimum TAVALISSE revenue covenant, $20M minimum liquidity covenant, and borrowing base collateral structure. No specific new grants, amounts issued, or material changes to prior plans disclosed in this exhibit filing.
Why this rating
Routine plan documentation and credit agreement amendment. No material new issuances, counterparty changes, or covenant violations evident. Standard maintenance of financing infrastructure.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.